KemPharm (KMPH) Reports In-Line Q3 EPS

KemPharm (NASDAQ: KMPH) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $2.97 million.

For earnings history and earnings-related data on KemPharm (KMPH) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c